The second messenger cyclic nucleotides, cyclic AMP and cyclic GMP, mediate relaxation of airways smooth muscle and suppression of multiple inflammatory cell functions. The intracellular concentrations of these cyclic nucleotides are regulated by a superfamily of phosphodiesterase (PDE) enzymes which break down cAMP and cGMP and, thereby, affect airway tone and inflammation. Theophylline and other drugs that act through inhibition of PDE are currently the subject of great research interest, since the uncovering of their anti-inflammatory actions suggests a possible additional mode of action in inflammatory diseases such as asthma. The characterisation of multiple families of PDE isoenzymes with distinct tissue distributions has encouraged hope that selective PDE inhibitors can be developed which act at specific targets without exhibiting the side effects of non-selective inhibitors like theophylline. The combination of bronchodilator and anti-inflammatory properties in a single drug by selective inhibition of specific PDE isoenzymes could produce agents most efficacious in every way for asthma therapy. (Thorax 1996;51:647-649) weekly; several of these drugs are now undergoing clinical trials.' The motive for this research effort is the desire to develop drugs that combine the bronchodilator actions of adrenoceptor agonists with a prophylactic action against the inflammatory processes that render the airways hyperreactive. The involvement of the cyclic nucleotide, adenosine 3',5'-cyclic monophosphate (cAMP), in the intracellular actions of agonists has long been established and PDE inhibition was adopted as an alternative approach to elevating cAMP levels while bypassing the complications of receptor downregulation and subsensitivity in severe episodes of bronchoconstriction.2 Similarly, the well established relationship between increased levels of cAMP and suppression of inflammatory cell function is a possible target for therapeutic interventions in inflammatory diseases, including asthma.3 Recent reports of immunomodulatory actions of low doses of theophylline -the archetypical PDE inhibitorsuggest that the clinical benefits of theophylline may be underlain by combined bronchodilator and anti-inflammatory attributes.45 While this work has renewed interest in theophylline, the prospects for drugs that selectively and potently inhibit one or two PDE isoenzymes are also the object of some excitement among asthma researchers.
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Conclusion
Although PDE isoenzymes are the object of great scientific interest, the development of inhibitors for the enzymes may remain of limited clinical importance for some time since most of the isoenzyme families are ubiquitous. The identification of subtypes of PDE within the families presents more narrowly defined targets for potential therapeutic actions of new inhibitors, although "third generation" PDE inhibitors, specific for a single subtype, are in their infancy. Should their potential be realised, with the modulation of defined target cell functions becoming achievable, medicinal compounds most efficacious in every way might be a reality for the treatment of asthma.
